Amferia closes €1,2 million investment to combat resistant bacterial infections
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. Investors include Chalmers Ventures. The deep tech company also signed its first commercial agreement with Orkla Wound Care during the second quarter of 2024 for commercialization of the company’s proprietary technology within the animal health segment, a wound dressing for animals that also kills resistant bacteria.Mölndal, Sweden (September 3rd, 2024): Amferia , a Swedish medtech company focused on developing